VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Trial details
- Registry ID
- NCT06264180
- Drugs studied
- Nivolumab, Nivolumab + Relatlimab, Pembrolizumab, Single-agent chemotherapy and 1 more